BACKGROUND: Successful management of pediatric low-grade glioma (pLGG) can be complicated by eloquent anatomical location, as well as specific pathologic and molecular features. Some authors have proposed using the VEGF inhibitor bevacizumab to improve disease control, but its safety and efficacy are poorly defined. Correspondingly, our aim was to pool systematically identified clinical data in the literature to assess the clinical utility of bevacizumab for pLGG at progression. METHODS: A systematic search of 7 electronic databases from inception to June 2019 was conducted following PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. Articles were screened against prespecified criteria. Outcomes were then pooled by random-effects meta-analyses of proportions. RESULTS: Seven pertinent studies described the outcomes of 110 progressive pLGG patients managed with bevacizumab in largely multiagent regimens. While on treatment, the rate of clinical response was 58% (95% CI, 43%-72%), and the rate of response on imaging was 80% (95% CI, 58%-96%). The rate of grade 3 or higher toxicity was 8% (95% CI, 2%-17%), with proteinuria the most commonly described. In the off-treatment period up to median 1 year, the rate of progression was estimated to be 51% (95% CI, 28%-74%). CONCLUSIONS: Bevacizumab has the potential to control clinical and radiographic disease with relatively low grade 3 or higher toxicity risk in progressive pLGG patients. However, the long-term off-treatment benefits of this therapy are not yet well defined. Heterogeneity in the literature precludes any formal recommendations regarding its use until larger, more standardized investigations can be performed.
BACKGROUND: Successful management of pediatric low-grade glioma (pLGG) can be complicated by eloquent anatomical location, as well as specific pathologic and molecular features. Some authors have proposed using the VEGF inhibitor bevacizumab to improve disease control, but its safety and efficacy are poorly defined. Correspondingly, our aim was to pool systematically identified clinical data in the literature to assess the clinical utility of bevacizumab for pLGG at progression. METHODS: A systematic search of 7 electronic databases from inception to June 2019 was conducted following PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. Articles were screened against prespecified criteria. Outcomes were then pooled by random-effects meta-analyses of proportions. RESULTS: Seven pertinent studies described the outcomes of 110 progressive pLGG patients managed with bevacizumab in largely multiagent regimens. While on treatment, the rate of clinical response was 58% (95% CI, 43%-72%), and the rate of response on imaging was 80% (95% CI, 58%-96%). The rate of grade 3 or higher toxicity was 8% (95% CI, 2%-17%), with proteinuria the most commonly described. In the off-treatment period up to median 1 year, the rate of progression was estimated to be 51% (95% CI, 28%-74%). CONCLUSIONS: Bevacizumab has the potential to control clinical and radiographic disease with relatively low grade 3 or higher toxicity risk in progressive pLGG patients. However, the long-term off-treatment benefits of this therapy are not yet well defined. Heterogeneity in the literature precludes any formal recommendations regarding its use until larger, more standardized investigations can be performed.
Authors: Eugene I Hwang; Regina I Jakacki; Michael J Fisher; Lindsay B Kilburn; Marianna Horn; Gilbert Vezina; Brian R Rood; Roger J Packer Journal: Pediatr Blood Cancer Date: 2012-09-13 Impact factor: 3.167
Authors: Dean W Beebe; M Douglas Ris; F Daniel Armstrong; John Fontanesi; Raymond Mulhern; Emi Holmes; Jeffrey H Wisoff Journal: J Clin Oncol Date: 2005-08-01 Impact factor: 44.544
Authors: Maryam Fouladi; Dana Wallace; James W Langston; Raymond Mulhern; Susan R Rose; Amar Gajjar; Robert A Sanford; Thomas E Merchant; Jesse J Jenkins; Larry E Kun; Richard L Heideman Journal: Cancer Date: 2003-02-15 Impact factor: 6.860
Authors: David T W Jones; Mark W Kieran; Eric Bouffet; Sanda Alexandrescu; Pratiti Bandopadhayay; Miriam Bornhorst; David Ellison; Jason Fangusaro; Michael J Fisher; Nicholas Foreman; Maryam Fouladi; Darren Hargrave; Cynthia Hawkins; Nada Jabado; Maura Massimino; Sabine Mueller; Giorgio Perilongo; Antoinette Y N Schouten van Meeteren; Uri Tabori; Katherine Warren; Angela J Waanders; David Walker; William Weiss; Olaf Witt; Karen Wright; Yuan Zhu; Daniel C Bowers; Stefan M Pfister; Roger J Packer Journal: Neuro Oncol Date: 2018-01-22 Impact factor: 12.300
Authors: Scott R Plotkin; Dan G Duda; Alona Muzikansky; Jeffrey Allen; Jaishri Blakeley; Tena Rosser; Jian L Campian; D Wade Clapp; Michael J Fisher; James Tonsgard; Nicole Ullrich; Coretta Thomas; Gary Cutter; Bruce Korf; Roger Packer; Matthias A Karajannis Journal: J Clin Oncol Date: 2019-10-18 Impact factor: 44.544
Authors: R Bowman; B Walters; V Smith; K L Prise; S E Handley; K Green; K Mankad; P O'Hare; C Dahl; M Jorgensen; E Opocher; D Hargrave; D A Thompson Journal: Eye (Lond) Date: 2022-05-13 Impact factor: 3.775